ArticleFrontiers in public health2025
Serological screening for specific antibodies against TORCH pathogens in reproductive-aged women in Zhangzhou, China.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: TORCH is a group of pathogens including Herpes simplex virus (HSV), Cytomegalovirus (CMV), Rubella virus (RV) and Toxoplasma gondii (TOX). Serological screening for the specific antibodies against TORCH pathogens is crucial for preventing fetal malformation and miscarriage. In this study, we analyzed the characteristics of TORCH IgM and IgG seropositivity in reproductive-aged women in Zhangzhou, China. Methods: A total of 1,417 reproductive-aged women prior to conception attended prenatal diagnosis outpatient clinic in Zhangzhou and received the prenatal TORCH serological screening were enrolled in this study. The IgM and IgG antibodies against TORCH pathogens were detected using chemiluminescence immunoassay. Results: The positive rates of IgM for TOX, RV, CMV and HSV-1/2 were 0.64, 2.33, 1.34 and 11.22%. The IgG seropositivity for TOX, RV, CMV, HSV-1 and HSV-2 were 3.81, 72.83, 97.46, 82.64 and 7.27%. The positive rate of HSV-1/2-IgM and TOX-IgG in 2024 were lower than that in 2023. In addition, the positive rates of RV-IgG and HSV-1-IgG were significantly higher in the women aged 30-34 years old and ≥35 years old. The CMV-IgM and HSV-2-IgG positive rates were higher in women ≥35 years old. Regarding seasonal distribution, the positive rate of HSV-1/2-IgM was significantly higher in spring (March to May) than that in winter (December to February). The seropositivity of all TORCH-IgG showed no significant differences across four seasons. Conclusion: Our research highlights the age and seasonal distribution of TORCH seroprevalence in reproductive-aged women in Zhangzhou. These findings underscore that continuous serological surveillance is important for the prevention of congenital infections caused by TORCH pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.